CS Medica Past Earnings Performance
Past criteria checks 0/6
CS Medica's earnings have been declining at an average annual rate of -50.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 22.5% per year.
Key information
-50.2%
Earnings growth rate
-55.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 22.5% |
| Return on equity | -676.9% |
| Net Margin | -263.8% |
| Next Earnings Update | 30 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CS Medica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5 | -12 | 14 | 0 |
| 31 Mar 24 | 5 | -13 | 16 | 0 |
| 31 Dec 23 | 3 | -14 | 16 | 0 |
| 30 Sep 23 | 1 | -15 | 17 | 0 |
| 30 Jun 23 | 10 | -11 | 16 | 0 |
| 31 Mar 23 | 11 | -11 | 17 | 0 |
| 31 Dec 22 | 11 | -12 | 18 | 0 |
| 30 Sep 22 | 11 | -11 | 17 | 0 |
| 30 Jun 22 | 4 | -10 | 14 | 0 |
| 31 Mar 22 | 3 | -5 | 9 | 0 |
| 31 Dec 21 | 3 | -2 | 5 | 0 |
| 30 Sep 21 | 3 | 1 | 2 | 0 |
| 30 Jun 21 | 1 | 0 | 2 | 0 |
| 30 Sep 20 | 2 | 0 | 1 | 0 |
| 30 Sep 19 | 1 | 0 | 0 | 0 |
Quality Earnings: 8G8 is currently unprofitable.
Growing Profit Margin: 8G8 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8G8 is unprofitable, and losses have increased over the past 5 years at a rate of 50.2% per year.
Accelerating Growth: Unable to compare 8G8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8G8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 8G8 has a negative Return on Equity (-676.93%), as it is currently unprofitable.